Differences in Presentation of SARS-CoV-2 Omicron Strain Variant BA.1-BA.5 Peptides by HLA Molecules.

S A Nersisyan, M Yu Shkurnikov, A P Zhiyanov, V O Novosad, A G Tonevitsky
Author Information
  1. S A Nersisyan: Laboratory of Microfluidic Technologies for Biomedicine, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. snersisyan@hse.ru.
  2. M Yu Shkurnikov: Laboratory of Microfluidic Technologies for Biomedicine, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
  3. A P Zhiyanov: Laboratory of Microfluidic Technologies for Biomedicine, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
  4. V O Novosad: Laboratory of Microfluidic Technologies for Biomedicine, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
  5. A G Tonevitsky: Laboratory of Microfluidic Technologies for Biomedicine, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Abstract

In this work, we analyzed the binding affinities of mutated peptides of Omicron strain variants BA.1-BA.5 and the worldwide prevalent HLA alleles. Bioinformatics analysis was conducted with the use of T-CoV web portal. We showed that, for all five viral variants, mutations cause a significant reduction in the number of tightly binding peptides for HLA-B*07:02 and HLA-C*01:02 molecules. At the same time, there were novel potential mutant epitopes (binding affinity less than 50 nM) in case of HLA-A*32:01 allele. Interestingly, mutations caused multidirectional effect on the binding affinities of the viral peptides and HLA-DRB1*03:01. Specifically, Spike protein mutations in the BA.1 variant caused more than 100-fold decrease in PINLVRDLPQGFSAL binding affinity, 10-fold decrease in affinity in the case of BA.2, BA.4, and BA.5 variants, and 30% increase in affinity for the BA.3 variant.

Keywords

References

  1. Sci Immunol. 2021 Mar 4;6(57): [PMID: 33664060]
  2. Cell. 2020 Oct 1;183(1):158-168.e14 [PMID: 32979941]
  3. Front Immunol. 2021 Feb 23;12:641900 [PMID: 33732261]
  4. Eur J Med Res. 2021 Aug 3;26(1):84 [PMID: 34344463]
  5. Nature. 2022 Feb;602(7898):671-675 [PMID: 35016199]
  6. Nucleic Acids Res. 2020 Jul 2;48(W1):W449-W454 [PMID: 32406916]
  7. PeerJ. 2022 Apr 27;10:e13354 [PMID: 35502206]
  8. Front Immunol. 2022 Feb 03;13:769900 [PMID: 35185875]
  9. Glob Chall. 2017 Jan 10;1(1):33-46 [PMID: 31565258]
  10. Cell Host Microbe. 2021 Jul 14;29(7):1124-1136.e11 [PMID: 34171266]
  11. Nucleic Acids Res. 2022 Jan 7;50(D1):D883-D887 [PMID: 34396391]
  12. Cell Host Microbe. 2021 Jul 14;29(7):1076-1092 [PMID: 34237248]
  13. Nature. 2022 Mar;603(7902):693-699 [PMID: 35062016]

MeSH Term

Humans
Computational Biology
COVID-19
Epitopes
Peptides
SARS-CoV-2
HLA Antigens

Chemicals

Epitopes
Peptides
HLA Antigens

Word Cloud

Created with Highcharts 10.0.0BAbindingaffinitypeptidesOmicronvariants5HLAmutationsaffinities1-BAT-CoVviralcasecausedvariantdecreaseSARS-CoV-2workanalyzedmutatedstrainworldwideprevalentallelesBioinformaticsanalysisconductedusewebportalshowedfivecausesignificantreductionnumbertightlyHLA-B*07:02HLA-C*01:02moleculestimenovelpotentialmutantepitopesless50nMHLA-A*32:01alleleInterestinglymultidirectionaleffectHLA-DRB1*03:01SpecificallySpikeprotein1100-foldPINLVRDLPQGFSAL10-fold2430%increase3DifferencesPresentationStrainVariantPeptidesMoleculesmutationpeptidepresentation

Similar Articles

Cited By